Document Type

Journal Article

Department/Unit

School of Chinese Medicine

Language

English

Abstract

Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC.

Keywords

molecular mechanism, translational therapy, HER2 positive breast cancer, diagnostic tests, monoclonal antibodies, small molecular inhibitors, antibody–drug conjugates

Publication Date

12-2016

Source Publication Title

International Journal of Molecular Sciences

Volume

17

Issue

12

Start Page

2095

Publisher

MDPI

Peer Reviewed

1

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Funder

This study was supported by the Hong Kong General Research Fund (HKBU12102914 to Ge Zhang), the Faculty Research Grant of Hong Kong Baptist University (FRG2/12-­‐‑13/027 to Ge Zhang) and National Natural Science Foundation of China (NSFC 81601929 to Yuanyuan Yu).

DOI

10.3390/ijms17122095

Link to Publisher's Edition

http://dx.doi.org/10.3390/ijms17122095

ISSN (print)

16616596

ISSN (electronic)

14220067

Share

COinS